Kuros Biosciences AG
SIX:KURN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.16
31.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one KURN stock under the Base Case scenario is 5.96 CHF. Compared to the current market price of 20.6 CHF, Kuros Biosciences AG is Overvalued by 71%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Kuros Biosciences AG
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
Historical valuation for KURN cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Kuros Biosciences AG
Balance Sheet Decomposition
Kuros Biosciences AG
Current Assets | 33.2m |
Cash & Short-Term Investments | 13.7m |
Receivables | 11m |
Other Current Assets | 8.5m |
Non-Current Assets | 44.1m |
PP&E | 2.9m |
Intangibles | 40.9m |
Other Non-Current Assets | 209k |
Current Liabilities | 12.2m |
Accounts Payable | 2.8m |
Accrued Liabilities | 8.7m |
Other Current Liabilities | 605k |
Non-Current Liabilities | 5m |
Long-Term Debt | 5m |
Earnings Waterfall
Kuros Biosciences AG
Revenue
|
52.5m
CHF
|
Cost of Revenue
|
-11m
CHF
|
Gross Profit
|
41.6m
CHF
|
Operating Expenses
|
-50.8m
CHF
|
Operating Income
|
-9.2m
CHF
|
Other Expenses
|
336k
CHF
|
Net Income
|
-8.9m
CHF
|
Free Cash Flow Analysis
Kuros Biosciences AG
CHF | |
Free Cash Flow | CHF |
KURN Profitability Score
Profitability Due Diligence
Kuros Biosciences AG's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Kuros Biosciences AG's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
KURN Solvency Score
Solvency Due Diligence
Kuros Biosciences AG's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Kuros Biosciences AG's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KURN Price Targets Summary
Kuros Biosciences AG
Dividends
Current shareholder yield for KURN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
KURN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Contact
IPO
Employees
Officers
The intrinsic value of one KURN stock under the Base Case scenario is 5.96 CHF.
Compared to the current market price of 20.6 CHF, Kuros Biosciences AG is Overvalued by 71%.